The etiology, pathogenesis, treatment, and development of transdermal drug delivery systems for rheumatoid arthritis-Reference-Cited by-同舟云学术

The etiology, pathogenesis, treatment, and development of transdermal drug delivery systems for rheumatoid arthritis

Published:2024 Issue: Volume: Page:
ISSN:2976-8713
Container-title:RSC Pharmaceutics
language:en
Short-container-title:RSC Pharm.

Author:

Baig Mirza Muhammad Faran Ashraf¹²^ORCID,Kwan Chi Hin²,Wu Hongkai²^ORCID,Chair Sek Ying¹

Affiliation:

1. Croucher Laboratory for Human Genomics, Asia-Pacific Genomic and Genetic Nursing Center, The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China

2. Department of Chemistry, and the Hong Kong Branch of Chinese National Engineering Research Centre for Tissue Restoration, The Hong Kong University of Science and Technology, Hong Kong SAR 999077, China

Abstract

Rheumatoid arthritis (RA) is a long-term autoimmune disease that causes irreversible deformity of joints and disability of body parts. To avoid adverse effects of drugs the existing transdermal delivery techniques can be further developed or improved.

Funder

Research Grants Council, University Grants Committee

Innovation and Technology Commission

Natural Science Foundation of Guangdong Province

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/PM/D4PM00085D

Reference174 articles.

1. Innate immunity drives pathogenesis of rheumatoid arthritis

2. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings

3. Economic Evaluation Of Tofacitinib Compared With Biological Therapy As Initial Medication After Failure To Methotrexate In Adults With Rheumatoid Arthritis In Colombia

4. PBI4 BUDGET IMPACT ANALYSIS OF GOLIMUMAB IN ADULT RHEUMATOID ARTHRITIS PATIENTS IN KINGDOM OF SAUDI ARABIA

5. Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry